skip to content

Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.